RXRX241129P9000
- 0.00
- 0.000.00%
Recursion Pharmaceuticals Newsroom
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Cathie Wood's ARK Investment Buys 383K Shares of Recursion Pharmaceuticals Today
Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Strategic Mergers and Financial Strength: Recursion Pharmaceuticals' Path to Growth
Recursion Pharmaceuticals' Strategic Acquisition and Leadership Changes
Recursion Completes Merger With Exscientia, Launches Comprehensive AI-Enabled Drug Discovery Portfolio
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery
Recursion Pharmaceuticals Call Volume Above Normal and Directionally Bullish
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
Arm Falls 6%: Nvidia 13F Shows Decreased Stake In Arm Holdings By 13%
Trending Industry Today: Recursion Pharmaceuticals Leads Losses In NVIDIA Portfolio Stocks